FGF21 and obesity due to melanocortin 4 receptor deficiency: LY2405319 (Eli Lilly and Company, Indianapolis, IN) is a modified human recombinant FGF21 analog engineered for increased stability and retained metabolic benefits and has been successfully used to treat obesity and hyperglycemia in rodent and primate models (10, 11).